Tech Reporter Virgin Islands
SEE OTHER BRANDS

The latest science and technology news from the U.S. Virgin Islands

Tech Reporter Virgin Islands: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Reporter Virgin Islands.

Press releases published on June 18, 2025

Zefiro Subsidiary Awarded USD $19.6 Million Plugging & Abandonment Management Contract from the Ohio Department of Natural Resources

Zefiro Subsidiary Awarded USD $19.6 Million Plugging & Abandonment Management Contract from the Ohio Department of Natural Resources

FORT LAUDERDALE, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- ZEFIRO METHANE CORP. (Cboe Canada: ZEFI) (Frankfurt: Y6B) (OTCQB: ZEFIF) (the “Company”, “Zefiro”, or “ZEFI”) is pleased to announce that its wholly owned subsidiary, Plants …

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock: …

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer  FDA recommends inclusion of patients as young as 6 months – younger than Moleculin had proposed – to be allowed in the pediatric …

F2G Announces Publication in The Lancet Infectious Diseases of Phase 2b Data Demonstrating Positive Therapeutic Responses in Patients with Serious Invasive Fungal Diseases Treated with Oral Olorofim

F2G Announces Publication in The Lancet Infectious Diseases of Phase 2b Data Demonstrating Positive Therapeutic Responses in Patients with Serious Invasive Fungal Diseases Treated with Oral Olorofim

MANCHESTER, United Kingdom, June 18, 2025 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company developing olorofim, a novel therapy to treat life-threatening rare fungal infections with high unmet medical need, today announced the …

Microchip Enhances Digital Signal Controller Lineup with Industry-Leading PWM Resolution and ADC Speed

Microchip Enhances Digital Signal Controller Lineup with Industry-Leading PWM Resolution and ADC Speed

CHANDLER, Ariz., June 18, 2025 (GLOBE NEWSWIRE) -- Evolving security and functional safety demands, coupled with the growing complexity of real-time embedded applications, are driving designers to seek innovative solutions that deliver greater accuracy, …

Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China

Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China

BOSTON and SHANGHAI, June 18, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first …

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. “ …

I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025

I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025

Virtual investor event planned for July 8th at 2:00pm EDT Event to follow presentation of new Phase 1b combination dose escalation data for givastomig (Claudin 18.2 x 4-1BB bispecific antibody) at ESMO GI on July 2, 2025 ROCKVILLE, Md., June 18, 2025 ( …

Climb Channel Solutions Announces North American Alliance with Bugcrowd

Climb Channel Solutions Announces North American Alliance with Bugcrowd

EATONTOWN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) is pleased to announce a new North American …

Gogo successfully completes first 5G end-to-end call.

Gogo successfully completes first 5G end-to-end call.

Broomfield, CO., June 18, 2025 (GLOBE NEWSWIRE) -- Broomfield, CO./ June 18, 2025 – Gogo (NASDAQ: GOGO) confirms today that GCT Semiconductor has successfully completed the very first end-to-end call using its next-generation 5G technology. The call, which …

Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of …

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients experiencing relapse or death within 12 months2 Management releases …

Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)

Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that data from across the SYMBRAVO® (meloxicam …

BPGbio Announces Presentation of Preliminary Clinical Data of Investigational BPM31510 for Primary CoQ10 Deficiency

BPGbio Announces Presentation of Preliminary Clinical Data of Investigational BPM31510 for Primary CoQ10 Deficiency

BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development. The Company plans to seek guidance in Q3 2025 from the FDA regarding the development of BPM31510 for PCQD …

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025; with Phase I …

3D Systems Announces Issuance of $92 Million of Convertible Senior Secured Notes due 2030 and Retirement of $180 Million of Existing Convertible Senior Notes due 2026

3D Systems Announces Issuance of $92 Million of Convertible Senior Secured Notes due 2030 and Retirement of $180 Million of Existing Convertible Senior Notes due 2026

ROCK HILL, S.C., June 18, 2025 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE: DDD) announced that it has entered into separate, privately negotiated subscription agreements with a limited number of qualified institutional buyers, pursuant to which 3D Systems …

ARRAY Technologies to Acquire APA Solar

ARRAY Technologies to Acquire APA Solar

Adds domestically manufactured engineered foundations and fixed-tilt solutions to product portfolio, expanding addressable market by nearly 40% Enables integrated tracker + foundation system to address challenging soil conditions, which does not require …

Fin du RTC : Les 6 questions les plus fréquentes sur le réseau téléphonique commuté (RTC)

Fin du RTC : Les 6 questions les plus fréquentes sur le réseau téléphonique commuté (RTC)

Le RTC désigne le système téléphonique analogique traditionnel reposant sur une infrastructure de lignes en cuivre. Il a distribué pendant des décennies les appels vocaux, et les communications vers les télécopieurs et les modems. Reconnu pour sa fiabilité …

Jeremy CHONG est nommé Marketing Manager chez nLighten France

Jeremy CHONG est nommé Marketing Manager chez nLighten France

nLighten, plateforme européenne d’infrastructure numérique de premier plan et spécialiste des datacenters de proximité, annonce la nomination de Jeremy CHONG au poste de Marketing Manager France. Avec 7 Edge datacenters répartis sur le territoire français …

Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board

Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board

NEW YORK and PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service